Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

Rhea-AI Summary

Trevi Therapeutics, a clinical-stage biopharmaceutical company developing Haduvio™ for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), announced its participation in upcoming commercial and investor conferences. The company's senior management will attend three events:

1. 3rd Chief Commercial Officer Summit in Philadelphia, PA (October 23-24, 2024), where Farrell Simon will present on Commercial's Role in Clinical Trial Recruitment.

2. BIO-Europe in Stockholm, Sweden (November 4-6, 2024), with Farrell Simon representing Trevi.

3. Stifel 2024 Healthcare Conference in New York, NY (November 18-19, 2024), featuring a corporate presentation by Jennifer Good and Lisa Delfini.

These events provide opportunities for Trevi to showcase its progress in developing Haduvio™ and engage with industry professionals and investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., Oct. 15, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in October and November.

3rd Chief Commercial Officer Summit
October 23-24, 2024, Philadelphia, PA
Oral Presentation: Commercial's Role in Clinical Trial Recruitment
Presentation: October 23, 1:30pm EDT 
Trevi Representative: Farrell Simon, Chief Commercial Officer
Register here

BIO-Europe
November 4-6, 2024, Stockholm Sweden
Trevi Representative: Farrell Simon, Chief Commercial Officer
Register here

Stifel 2024 Healthcare Conference
November 18-19, 2024, New York, NY
Corporate Presentation: November 18, 11:30am EDT 
Trevi Representatives: Jennifer Good, President and CEO, Lisa Delfini, Chief Financial Officer
Register here to watch the live presentation

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is an extended-release (ER) dual ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough. Parenteral nalbuphine is not scheduled by the U.S. Drug Enforcement Agency.

The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal benefit to patients. Chronic cough affects up to 10% of the adult population, and Haduvio's expansion into RCC has the potential to reach patients suffering from moderate to severe refractory chronic cough. There are also no approved therapies for RCC in the U.S.

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.

Investor Contact
Katie Barrett
Trevi Therapeutics, Inc.
203-304-2499
k.barrett@trevitherapeutics.com 

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-commercial-and-investor-conferences-302275584.html

SOURCE Trevi Therapeutics, Inc.

FAQ

What conferences will Trevi Therapeutics (TRVI) attend in October and November 2024?

Trevi Therapeutics (TRVI) will attend the 3rd Chief Commercial Officer Summit in Philadelphia (October 23-24), BIO-Europe in Stockholm (November 4-6), and the Stifel 2024 Healthcare Conference in New York (November 18-19).

Who will represent Trevi Therapeutics (TRVI) at the upcoming conferences?

Farrell Simon (Chief Commercial Officer) will represent Trevi at the 3rd Chief Commercial Officer Summit and BIO-Europe. Jennifer Good (President and CEO) and Lisa Delfini (Chief Financial Officer) will present at the Stifel 2024 Healthcare Conference.

What is Trevi Therapeutics (TRVI) developing Haduvio™ for?

Trevi Therapeutics (TRVI) is developing Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

When and where will Trevi Therapeutics (TRVI) present at the Stifel 2024 Healthcare Conference?

Trevi Therapeutics (TRVI) will present at the Stifel 2024 Healthcare Conference on November 18, 2024, at 11:30am EDT in New York, NY.